_256_384.jpg)
In FY21, the company reported a net profit of Rs 419 crores compared to Rs 101 crores in FY 20 and consolidated total income at Rs 6092 crores, up 19% Y-o-Y
The financing secures funds to advance the clinical development of EpiEndo’s lead compound EP395, which entered phase I clinical trials in April, through Phase IIa, targeting COPD as a primary indication
The funds will be used to buy medicines, enhance oxygen supply and augment the bed capacity in the local and district level hospitals
Rs one crore for each district to create medicine pool and support Centre of Excellence for Telemedicine
'Unit-9' for manufacturing Gabapentin & other pharma (APIs) products is expected to be complete in Q3FY22
The company reports revenue growth of 26% and PAT growth of 21% YoY
It strengthens Syngene’s portfolio as a fully integrated custom biomanufacturer with added mammalian and microbial capabilities for clinical and commercial supplies
The acquisition will provide it with a foothold in the US $ 48 billion global animal health market
Income declines marginally
The company has strong product launches both in India and overseas
Subscribe To Our Newsletter & Stay Updated
